Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
Abstract
Clinical efficacy and normalised CRP at week 12 (early deep clinical remission) are associated with medium-term clinical efficacy and mucosal healing during adalimumab therapy, whereas need for combined immunosuppression at induction and smoking status are predictors for non-response. Parallel azath …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
logistic models
treatment outcome
adult
female
male
young adult
Remission Induction
Prospective Studies
Antibodies
Monoclonal
follow-up studies
intestinal mucosa / immunology
time factors
dose-response relationship
drug
predictive value of tests
crohn disease / drug therapy*
anti-inflammatory agents / administration & dosage*
intestinal mucosa / drug effects*
adalimumab
c-reactive protein / metabolism*
humanized / administration & dosage*
investigators=[]
affs=[])
pmid:21883326
doi:10.1111/j.1365-2036.2011.04827.x
l s kiss
t szamosi
collabauthor(name='hungarian ibd study group'
crohn disease / blood
Access
Citation
ID:
270102
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
270102
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet